Press Release Archive

 
03.23.2021 - Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021.

 
03.11.2021 - Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
*/ /*-->*/ /*-->*/
  • Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health  
  • Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2
 
03.08.2021 - Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
  • The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program  
  • VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg
  • VLA15 is the only Lyme disease vaccine candidate in active clinical development

Saint-Herblain (France) and New York, NY, March 8, 2021Valneva SE (“Valneva”), a s

 
03.04.2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 1:15 p.m. Eastern Standard Time.

 
03.03.2021 - U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
*/ /*-->*/ /*-->*/

Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI®

 
02.26.2021 - European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
*/ /*-->*/ /*-->*/

If approved, the vaccine would help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia

 
02.26.2021 - EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
*/ /*-->*/ /*-->*/

– If approved, somatrogon will serve as a once-weekly treatment option –

 
02.25.2021 - Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
*/ /*-->*/ /*-->*/
  • The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
  • Discussions with regulato
 
02.23.2021 - U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
*/ /*-->*/ /*-->*/

Tick-borne encephalitis (TBE) is a viral infection, endemic to parts of Europe and Asia

If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations

 
02.22.2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021 at 3:20 p.m. Eastern Standard Time.

 
02.19.2021 - Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
  • Proposed U.S. EUA label update would enable the vaccine to be stored at -25°C to -15°C (-13°F to 5°F) for a total of two weeks
  • If approved, new storage option could offer pharmacies and vaccination centers greater flexibility in managing and maintaining vaccine distribution and supply

NEW YORK and MAINZ, GERMANY, February 19, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the submission of new data to the U.S.

 
02.18.2021 - Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women

New York, USA and Mainz, Germany, February 18, 2021 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine(BNT162

 
02.17.2021 - Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

BASEL, Switzerland and NEW YORK, February 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc.

 
02.17.2021 - Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma.

 
02.17.2021 - Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
*/ /*-->*/ /*-->*/
  • New agreement brings total supply to the European Union to 500 million doses, with delivery expected by the end of 2021
  • European Commission has the option to request an additional 100 million doses

NEW YORK & MAINZ, Germany--(BUSINESS WI

 
02.17.2021 - In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations

New York, NY and Mainz, Germany, February 17, 2021 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to neutralize SARS-CoV-2 with the South African variant spike protein.

 
02.12.2021 - Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

U.S. government exercises option to bring total supply to 300 million doses, enabling vaccinations for 150 million people

 
02.09.2021 - Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries

NEW YORK, February 9, 2021 - Pfizer today announced a partnership with IDA Foundation, an independent social enterprise providing essential medicines to low-and middle-income countries, to provide equitable access to quality cancer treatments in almost 70 developing countries across Latin America, Asia, Africa and the Wester

 
02.08.2021 - Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants
New York, NY and Mainz, Germany, February 8, 2021Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from individuals vaccinated with the Pfizer- BioNTech COVID-19 vaccine neutralize SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South African variants.

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.